- REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect -

- Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively, versus 15% placebo, both highly statistically significant results (p < 0.0001) -

- Elegrobart Q4W achieved a statistically significant 61% diplopia responder rate at week 24, versus 38% placebo (p = 0.0118) -

- Elegrobart was generally well tolerated in both dose groups, with a safety profile consistent with REVEAL‑1 and low rates of hearing impairment -

- Elegrobart is the only subcutaneous program to demonstrate positive phase 3 data in both active and chronic TED pivotal clinical trials and has the potential to be the first autoinjector treatment for TED; BLA submission on track for Q1 2027 -